Sir - Broom et al. (1992) have reported an interesting observation on the inverse correlation between pretreatment serum C-reactive protein (CRP) and response to interleukin 2 (IL-2) in patients with metastatic colorectal cancer. We would like to report a similar observation in metastatic renal carcinoma.
Serum CRP levels were measured the day before starting therapy in 121 patients with metastatic renal carcinoma treated with IL-2 between 1987 and 1991 and who were evaluable for response. None of these patients had evidence of infection at the time of sample. Three different IL-2-containing regimens were used: 56 patients received continuous intravenous (i.v.) IL-2, 28 bolus i.v. IL-2 with interferon alpha (IFN) and LAK cells and 37 subcutaneous IL-2 and IFN (Blay et al., 1992) . As previously reported, serum CRP levels were highly correlated to serum IL-6 in these patients (Blay et al., 1992) .
Patients who experienced progressive disease after IL-2 had significantly higher pretreatment CRP levels than other patients (P< 0.001, Table I ). Only one of the 37 (3%) patients with pretreatment serum CRP over 50 mg 1-1 achieved response to IL-2 compared with 20 of the 84 (24%) remaining patients (two-tailed Fisher's exact test: P = 0.007). These results demonstrate that pretreatment serum CRP levels are inversely correlated to the response to IL-2 in metastatic renal carcinoma.
These results indicate that serum CRP is inversely correlated to the response to IL-2 in two different tumour models (Broom et al., 1992) . Several interpretations could account for these observations. The increase in serum CRP could be related to the production of proinflammatory cytokines by tumour cells, such as IL-6, and thus be an index of tumour burden. However, no correlation between IL-6 and tumour mass was observed in patients with metastatic renal cancer (Blay et al., 1992) . Alternatively, serum CRP could by itself interfere with the immunological mechanisms involved in the anti-tumour activity of IL-2. CRP has been reported to play an important role in the cytotoxic activity of NK cells (Hamoudi & Baum, 1991) . CRP is also involved in the binding of complement to CD3+ cells in vivo in patients receiving IL-2, a phenomenon that contributes to endothelial injury during IL-2 treatment (Thijs et al., 1990; Vachino et al., 1991) . Conceivably, high levels of circulating CRP in these patients before IL-2 administration could interfere with the biological mechanisms responsible for the antineoplastic activity of IL-2 in vivo.
The observation that baseline serum CRP is inversely correlated to response to IL-2 in different tumours has important potential consequences for the selection of candidates for IL-2 therapy. The exact role of CRP in these observations remains to be elucidated. 
